For decades, the KRAS protein occupied a singular place in oncology's collective frustration. Present in roughly a quarter of all human cancers and dominant in pancreatic and lung malignancies, KRAS was widely considered the most important — and most intractable — target in cancer biology. Researchers understood its role as a molecular switch that, when mutated, locks cells into uncontrolled growth. They simply could not design a molecule to stop it. The protein's smooth, pocket-free surface offered no obvious binding site, earning it the label "undruggable" — a term that persisted for more than three decades. That label now appears outdated. New clinical data from Revolution Medicines on its drug daraxonrasib suggest meaningful efficacy in pancreatic cancer patients, marking a concrete advance in a field that had long promised more than it delivered.
The daraxonrasib results arrive in a broader context of molecular and cellular innovation that is reshaping the boundaries of what biotechnology can address. Novo Nordisk reported that its experimental oral drug etavopivat met Phase 3 endpoints for sickle cell disease, reducing pain crises and improving hemoglobin levels. And in immunotherapy, Eli Lilly is reportedly nearing a $2 billion acquisition of Kelonia Therapeutics, a company developing in-vivo CAR-T therapies — an approach that would reprogram a patient's immune cells inside the body rather than in a laboratory.
From undruggable to druggable: the long road to KRAS
The history of KRAS drug development is a case study in how scientific consensus can calcify around impossibility. The gene was identified as an oncogene in the early 1980s, and for the next four decades, hundreds of research programs attempted and failed to find a viable inhibitor. The breakthrough came with the discovery that a specific mutation — KRAS G12C — created a small, previously unrecognized pocket on the protein's surface. Amgen's sotorasib, approved in 2021 for non-small cell lung cancer, became the first KRAS inhibitor to reach the market, followed by Mirati Therapeutics' adagrasib. But those first-generation drugs targeted only one of several KRAS mutations, and their clinical benefits, while real, were modest in duration.
What makes the Revolution Medicines program notable is its ambition to go broader. Daraxonrasib is designed to inhibit multiple KRAS mutations, not just G12C, which is particularly relevant for pancreatic cancer, where G12D and G12V mutations predominate. Pancreatic ductal adenocarcinoma remains among the deadliest cancers, with five-year survival rates that have barely moved in decades. A drug that can meaningfully target the dominant driver mutation in this disease would represent not merely an incremental improvement but a shift in the therapeutic landscape.
Cellular engineering moves inside the patient
The potential Eli Lilly–Kelonia deal reflects a parallel shift in how the industry thinks about cell therapy. Traditional CAR-T therapy — in which a patient's T cells are extracted, genetically engineered to recognize cancer antigens, and reinfused — has produced durable remissions in certain blood cancers. But the process is expensive, logistically complex, and limited to specialized treatment centers. Manufacturing a personalized therapy for each patient creates bottlenecks that have constrained access.
In-vivo CAR-T aims to bypass that entire chain. The concept involves delivering genetic instructions — typically via a viral vector or lipid nanoparticle — directly into the patient's bloodstream, reprogramming T cells where they already reside. If the approach works at scale, it could transform CAR-T from a bespoke manufacturing exercise into something closer to an injectable drug. The acquisition price reportedly under discussion signals how seriously large pharmaceutical companies are taking this possibility, even at a stage where clinical validation remains early.
Taken together, these developments — KRAS inhibition expanding beyond its first narrow beachhead, oral therapies reaching late-stage trials for genetic blood disorders, and in-vivo cell engineering attracting major capital — suggest that biotechnology is entering a phase where foundational scientific advances are beginning to compound. The question is no longer whether these biological barriers can be breached, but how quickly the resulting therapies can be made reliable, affordable, and broadly accessible. Leadership turbulence within individual companies, such as the abrupt resignation of Helus Pharma CEO Michael Cola, serves as a reminder that institutional execution does not always keep pace with scientific possibility. The gap between what the science now permits and what the industry can deliver at scale remains the central tension to watch.
With reporting from STAT News.
Source · STAT News (Biotech)
